Lipo-Immuno TECH LLC
Mount Pleasant, SC
- UEI
- DH2EBEYDDJM9
- CAGE
- 841U1
- Primary NAICS
- 238990 All Other Specialty Trade Contractors
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Physical address
- 3064 Riverwood Dr, Mt Pleasant, SC 29466, USA
- Website
- lipo-immunotech.com
- Founded
- 2018
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
About the company
Lipo-Immuno TECH LLC, a Mt. Pleasant, South Carolina-based biotech small business, is a federal grant recipient focused on cancer immunotherapies and mitochondrial-targeting therapeutics, operating exclusively as a prime recipient under the National Cancer Institute (NCI) without subcontracting relationships or federal contract prime work.
The company originated from the Hollings Cancer Center at the Medical University of South Carolina and specializes in developing ceramide-analog drugs that induce lethal mitophagy and enhance immunotherapy response in solid tumors and hematologic malignancies. Lipo-Immuno TECH LLC holds a patent (US 12,390,490 B2, issued August 19, 2025) for LCL768 and its derivatives — a first-in-class C18-ceramide analog conjugate that accumulates selectively in cancer cell mitochondria, binds LC3B, recruits autophagosomes, and activates DRP1 to trigger mitophagy.
Across five federal grants, Lipo-Immuno TECH LLC has worked exclusively with the National Cancer Institute, with $4.2 million combined obligated. Current work includes a $348,352 fast-track STTR-R42 Phase I grant (awarded August 7, 2026, running through July 31, 2027) to optimize LCL768 and a backup analog for head and neck squamous cell carcinoma, targeting structure-activity relationship studies and on-target potency improvements with defined stop/go milestones. Prior NCI grants funded development of thioredoxin-based strategies to enhance adoptive T cell therapy persistence (awarded September 13, 2022, completed August 31, 2024) and ceramide-targeting approaches for acute myeloid leukemia mitophagy (awarded September 1, 2022, completed August 31, 2024). One award faces completion within the next twenty-four months, creating recompete opportunity. The company has no federal contract prime footprint and does not subcontract.
Quick answers
Is Lipo-Immuno TECH LLC registered in SAM.gov?
Yes. Lipo-Immuno TECH LLC's SAM.gov registration is active through February 9, 2027.
What is Lipo-Immuno TECH LLC's CAGE code?
Lipo-Immuno TECH LLC's CAGE code is 841U1, and its Unique Entity ID (UEI) is DH2EBEYDDJM9.
What is Lipo-Immuno TECH LLC's most recent federal award?
Lipo-Immuno TECH LLC's most recent federal grant award is Targeting mitochondria by ceramide in head and neck cancers (R42CA314463), from National Cancer Institute (NIH), on August 7, 2026.
On GovTribe
See Lipo-Immuno TECH LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors